Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding

Luisa Borgianni, Julie Vandenameele, André Matagne, Luca Bini, Robert A. Bonomo, Jean Marie Frère, Gian Maria Rossolini, Jean Denis Docquier

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Metallo-β-lactamase (MBL)-producing bacteria are emerging worldwide and represent a formidable threat to the efficacy of relevant β-lactams, including carbapenems, expanded-spectrum cephalosporins, and β-lactamase inactivator/β-lactam combinations. VIM-2 is currently the most widespread MBL and represents a primary target for MBL inhibitor research, the clinical need for which is expected to further increase in the future. Using a saturation mutagenesis approach, we probed the importance of four residues (Phe-61, Ala-64, Tyr-67, and Trp-87) located close to the VIM-2 active site and putatively relevant to the enzyme activity based on structural knowledge of the enzyme and on structure-activity relationships of the subclass B1 MBLs. The ampicillin MIC values shown by the various mutants were affected very differently depending on the randomized amino acid position. Position 64 appeared to be rather tolerant to substitution, and kinetic studies showed that the A64W mutation did not significantly affect substrate hydrolysis or binding, representing an important difference from IMP-type enzymes. Phe-61 and Tyr-67 could be replaced with several amino acids without the ampicillin MIC being significantly affected, but in contrast, Trp-87 was found to be critical for ampicillin resistance. Further kinetic and biochemical analyses of W87A and W87F variants showed that this residue is apparently important for the structure and proper folding of the enzyme but, surprisingly, not for its catalytic activity. These data support the critical role of residue 87 in the stability and folding of VIM-2 and might have strong implications for MBL inhibitor design, as this residue would represent an ideal target for interaction with small molecules.

Original languageEnglish
Pages (from-to)3197-3204
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume54
Issue number8
DOIs
Publication statusPublished - Aug 1 2010

Fingerprint

Lactams
Enzymes
Ampicillin
Ampicillin Resistance
Amino Acids
Inosine Monophosphate
Carbapenems
Cephalosporins
Structure-Activity Relationship
Mutagenesis
Catalytic Domain
Hydrolysis
Bacteria
Mutation
Research

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Borgianni, L., Vandenameele, J., Matagne, A., Bini, L., Bonomo, R. A., Frère, J. M., ... Docquier, J. D. (2010). Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding. Antimicrobial Agents and Chemotherapy, 54(8), 3197-3204. https://doi.org/10.1128/AAC.01336-09

Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding. / Borgianni, Luisa; Vandenameele, Julie; Matagne, André; Bini, Luca; Bonomo, Robert A.; Frère, Jean Marie; Rossolini, Gian Maria; Docquier, Jean Denis.

In: Antimicrobial Agents and Chemotherapy, Vol. 54, No. 8, 01.08.2010, p. 3197-3204.

Research output: Contribution to journalArticle

Borgianni, L, Vandenameele, J, Matagne, A, Bini, L, Bonomo, RA, Frère, JM, Rossolini, GM & Docquier, JD 2010, 'Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding', Antimicrobial Agents and Chemotherapy, vol. 54, no. 8, pp. 3197-3204. https://doi.org/10.1128/AAC.01336-09
Borgianni, Luisa ; Vandenameele, Julie ; Matagne, André ; Bini, Luca ; Bonomo, Robert A. ; Frère, Jean Marie ; Rossolini, Gian Maria ; Docquier, Jean Denis. / Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding. In: Antimicrobial Agents and Chemotherapy. 2010 ; Vol. 54, No. 8. pp. 3197-3204.
@article{4881ce435d5d4cc68030473e5d2476e3,
title = "Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding",
abstract = "Metallo-β-lactamase (MBL)-producing bacteria are emerging worldwide and represent a formidable threat to the efficacy of relevant β-lactams, including carbapenems, expanded-spectrum cephalosporins, and β-lactamase inactivator/β-lactam combinations. VIM-2 is currently the most widespread MBL and represents a primary target for MBL inhibitor research, the clinical need for which is expected to further increase in the future. Using a saturation mutagenesis approach, we probed the importance of four residues (Phe-61, Ala-64, Tyr-67, and Trp-87) located close to the VIM-2 active site and putatively relevant to the enzyme activity based on structural knowledge of the enzyme and on structure-activity relationships of the subclass B1 MBLs. The ampicillin MIC values shown by the various mutants were affected very differently depending on the randomized amino acid position. Position 64 appeared to be rather tolerant to substitution, and kinetic studies showed that the A64W mutation did not significantly affect substrate hydrolysis or binding, representing an important difference from IMP-type enzymes. Phe-61 and Tyr-67 could be replaced with several amino acids without the ampicillin MIC being significantly affected, but in contrast, Trp-87 was found to be critical for ampicillin resistance. Further kinetic and biochemical analyses of W87A and W87F variants showed that this residue is apparently important for the structure and proper folding of the enzyme but, surprisingly, not for its catalytic activity. These data support the critical role of residue 87 in the stability and folding of VIM-2 and might have strong implications for MBL inhibitor design, as this residue would represent an ideal target for interaction with small molecules.",
author = "Luisa Borgianni and Julie Vandenameele and Andr{\'e} Matagne and Luca Bini and Bonomo, {Robert A.} and Fr{\`e}re, {Jean Marie} and Rossolini, {Gian Maria} and Docquier, {Jean Denis}",
year = "2010",
month = "8",
day = "1",
doi = "10.1128/AAC.01336-09",
language = "English",
volume = "54",
pages = "3197--3204",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding

AU - Borgianni, Luisa

AU - Vandenameele, Julie

AU - Matagne, André

AU - Bini, Luca

AU - Bonomo, Robert A.

AU - Frère, Jean Marie

AU - Rossolini, Gian Maria

AU - Docquier, Jean Denis

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Metallo-β-lactamase (MBL)-producing bacteria are emerging worldwide and represent a formidable threat to the efficacy of relevant β-lactams, including carbapenems, expanded-spectrum cephalosporins, and β-lactamase inactivator/β-lactam combinations. VIM-2 is currently the most widespread MBL and represents a primary target for MBL inhibitor research, the clinical need for which is expected to further increase in the future. Using a saturation mutagenesis approach, we probed the importance of four residues (Phe-61, Ala-64, Tyr-67, and Trp-87) located close to the VIM-2 active site and putatively relevant to the enzyme activity based on structural knowledge of the enzyme and on structure-activity relationships of the subclass B1 MBLs. The ampicillin MIC values shown by the various mutants were affected very differently depending on the randomized amino acid position. Position 64 appeared to be rather tolerant to substitution, and kinetic studies showed that the A64W mutation did not significantly affect substrate hydrolysis or binding, representing an important difference from IMP-type enzymes. Phe-61 and Tyr-67 could be replaced with several amino acids without the ampicillin MIC being significantly affected, but in contrast, Trp-87 was found to be critical for ampicillin resistance. Further kinetic and biochemical analyses of W87A and W87F variants showed that this residue is apparently important for the structure and proper folding of the enzyme but, surprisingly, not for its catalytic activity. These data support the critical role of residue 87 in the stability and folding of VIM-2 and might have strong implications for MBL inhibitor design, as this residue would represent an ideal target for interaction with small molecules.

AB - Metallo-β-lactamase (MBL)-producing bacteria are emerging worldwide and represent a formidable threat to the efficacy of relevant β-lactams, including carbapenems, expanded-spectrum cephalosporins, and β-lactamase inactivator/β-lactam combinations. VIM-2 is currently the most widespread MBL and represents a primary target for MBL inhibitor research, the clinical need for which is expected to further increase in the future. Using a saturation mutagenesis approach, we probed the importance of four residues (Phe-61, Ala-64, Tyr-67, and Trp-87) located close to the VIM-2 active site and putatively relevant to the enzyme activity based on structural knowledge of the enzyme and on structure-activity relationships of the subclass B1 MBLs. The ampicillin MIC values shown by the various mutants were affected very differently depending on the randomized amino acid position. Position 64 appeared to be rather tolerant to substitution, and kinetic studies showed that the A64W mutation did not significantly affect substrate hydrolysis or binding, representing an important difference from IMP-type enzymes. Phe-61 and Tyr-67 could be replaced with several amino acids without the ampicillin MIC being significantly affected, but in contrast, Trp-87 was found to be critical for ampicillin resistance. Further kinetic and biochemical analyses of W87A and W87F variants showed that this residue is apparently important for the structure and proper folding of the enzyme but, surprisingly, not for its catalytic activity. These data support the critical role of residue 87 in the stability and folding of VIM-2 and might have strong implications for MBL inhibitor design, as this residue would represent an ideal target for interaction with small molecules.

UR - http://www.scopus.com/inward/record.url?scp=77955383826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955383826&partnerID=8YFLogxK

U2 - 10.1128/AAC.01336-09

DO - 10.1128/AAC.01336-09

M3 - Article

VL - 54

SP - 3197

EP - 3204

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -